Drugs / HPN424
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03577028 | Jul 2018 → Feb 2023 | prostate cancer | Harpoon Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPN424 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03577028 ↗ |
| Route | Intravenous | “HPN424 administered once weekly via IV infusion” NCT03577028 ↗ |